EdiGene develops proprietary genome-editing platforms, including ex vivo editing for hematopoietic stem cells and T cells, an in vivo RNA base-editing platform (LEAPER™), and high-throughput genome-editing screening to discover targeted therapies. The company’s lead candidate, ET-01 (a CRISPR/Cas9 therapy for transfusion-dependent β-thalassemia), received the first gene-editing and first hematopoietic stem cell therapy IND approval in China and is preparing for a Phase I trial. EdiGene is also advancing allogeneic CAR-T programs, in vivo RNA base-editing therapies, and other assets discovered via its screening platforms. Founded in 2015, the company is headquartered in Beijing and has offices/operations in Guangzhou, Shanghai and Cambridge, Massachusetts. Financially, EdiGene completed an RMB 400 million (approximately USD 62 million) Series B Plus financing and previously closed an RMB 450 million (approximately USD 67 million) Series B in October 2020. Proceeds from the new round will be used to advance pipeline candidates into the clinic and to scale up business operations, including newly opened clinical, business development, and R&D centers. EdiGene develops genome editing technologies and therapeutics across genetic diseases and oncology. Founded in 2015, the company has established four gene‑editing platforms: ex vivo platforms for hematopoietic stem cells and T cells, an in vivo RNA base‑editing platform, and high‑throughput genome‑editing screening. It opened a GMP manufacturing facility in Guangdong in 2018. EdiGene is advancing its early‑stage programs into clinical development and plans to use new proceeds to move its pipeline into clinics and expand the team. Financially, the company completed a RMB 450 million (approximately USD 67 million) Series B and reported having raised about RMB 700 million (USD 100 million) in the past two years. Headquarters are in Beijing, with subsidiaries in Guangzhou and Cambridge, Massachusetts. EdiGene translates genome‑editing technologies into novel therapeutics for a broad range of diseases and into solutions to advance drug discovery. The company leverages proprietary platforms to develop gene‑editing therapies and to perform high‑throughput genome screening. It has been building an allogeneic CAR‑T platform aimed at off‑the‑shelf T‑cell therapies. EdiGene recently formed a research collaboration with a clinical‑stage biopharmaceutical company to explore new allogeneic T‑cell therapeutic approaches for cancer; the partner and terms were not disclosed. The company completed an approximately $11 Million Series pre‑B2 financing with participation from IDG Capital and Lilly Asia Ventures. EdiGene was founded in 2015 and is headquartered in Beijing, with operational subsidiaries in Guangzhou, China and Cambridge, USA. EdiGene develops genome‑editing platforms to create novel therapeutics for genetic diseases and cancer and to enable high‑throughput genome screening for drug discovery. The company leverages proprietary gene‑editing technologies to advance therapeutic candidates toward clinical testing. It recently completed a financing round to support progression of its portfolio and clinic-directed activities. Management has been strengthened with the appointment of Yun Li, MD, as Vice President of Clinical Development to help advance hematology and oncology programs. EdiGene was founded in 2015 and is headquartered in Beijing, with operational subsidiaries in Guangzhou and Cambridge, Massachusetts. The company says the new financing validates and supports its strategy to translate platforms into potential therapeutics. EdiGene develops genome editing technologies into novel therapeutics for genetic diseases and cancer and builds high-throughput genome screening platforms to advance drug discovery. The company leverages proprietary platforms to develop gene-editing therapies and to conduct high-throughput screening that enables dissection of functional big data in biological contexts. EdiGene plans to continue advancing its portfolio of therapeutic programs and to further develop its High Throughput Genome Screening platforms into a comprehensive solution for partners in areas such as drug sensitivity, drug resistance and synthetic lethality. The company completed approximately $15 million in a Series pre-B financing to support these efforts. New investor Huagai Capital participated, along with Series A lead investor IDG Capital, Series A investor WI Harper Group and other insiders. Founded in 2015, EdiGene is headquartered in Beijing with operational subsidiaries in Guangzhou and Cambridge, Massachusetts.

Total raised

$164M

Funding rounds

5

Latest round

Series B

Latest activity

Apr 2021